Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Abstract Background Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma DNA (cfDNA) next‐generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor (T...

Descripción completa

Detalles Bibliográficos

Autores principales:	Minsuk Kwon, Bo mi Ku, Steve Olsen, Sehhoon Park, Martina Lefterova, Justin Odegaard, Hyun‐Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2022-08-01
Colección:	Cancer Medicine
Materias:	anaplastic lymphoma kinase‐rearranged (ALK+) NSCLC cell‐free DNA liquid biopsy next‐generation sequencing
Acceso en línea:	https://doi.org/10.1002/cam4.4663
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!